Clinical trials: Histological Response
Melanoma, Skin Cancer
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT02111863
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Follicular Lymphoma, Non-Hodgkin's Lymphoma
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Background: The disease follicular lymphoma (FL) develops when the body makes abnormal B-cells. These cells usually build up in the lymph nodes, but can also affect other parts of the body.
- Conditions
- Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
- Trial name
- NCT03789240
- Testing
- Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
CNDO-109-AANK for AML in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…
- Trial name
- NCT01520558
- Testing
- CNDO-109-AANK Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Coronado Biosciences, Inc.
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Malignant Glioma
Study of Capecitabine to Treat Recurrent High Grade Gliomas
The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
- Trial name
- NCT00717197
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT02057874
- Testing
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Mantle Cell Lymphoma
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
This single arm study will evaluate the benefit of adding MabThera to standard induction chemotherapy in patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT00472420
- Testing
- rituximab [MabThera/Rituxan], First line chemotherapy
- Where
- 7 sites in Hungary
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Follicular
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a…
- Trial name
- NCT02569996
- Testing
- Rituximab
- Where
- 21 sites in Hungary
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Chronic Myelomonocytic Leukemia
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
The primary objective of this study is: Response to treatment will be evaluated according to the revised International Working Group (IWG) categories natural history, hematologic improvement and cytogenetic response1;2.
- Trial name
- NCT01350947
- Testing
- 5-Azacitidine
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Melanoma, Skin Cancer
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT is a combination of three drugs - cisplatin, vinblastine, and temozolomide.
- Trial name
- NCT00885534
- Testing
- Cisplatin, Vinblastine, Temozolomide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
Neoadjuvant Pazopanib in Renal Cell Carcinoma
This study will be a single arm phase II clinical trial of 8 weeks of daily, oral neo-adjuvant pazopanib prior to nephrectomy in 39 evaluable patients with histologically confirmed localized renal cell carcinoma (RCC).
- Trial name
- NCT01361113
- Testing
- Pazopanib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Renal Cell Carcinoma, Hereditary Leiomyomatosis
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Background: There are no established treatments for people with certain advanced kidney cancers. These tumors often don't respond well to currently available treatments.
- Conditions
- Renal Cell Carcinoma, Hereditary Leiomyomatosis, Renal Cell Cancer
- Trial name
- NCT02495103
- Testing
- Vandetanib, Metformin, Vandetanib/Metformin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Histological Response of Tissue to Cold
Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects
This study is designed to characterize the biological response of the epidermis, dermis and subcutaneous tissue to treatment with the Myoscience Cryo-Touch III system.
- Trial name
- NCT01681745
- Testing
- Cryo-Touch III
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pacira Pharmaceuticals, Inc
Leukemia
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.
- Trial name
- NCT01893372
- Testing
- Eltrombopag, Hypomethylating Agent (HMA)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients who have melanoma lesions deep in the skin, in…
- Trial name
- NCT00059475
- Testing
- Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Chronic Myelomonocytic Leukemia
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
- Conditions
- Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT00843882
- Testing
- Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis
- Where
- 507 sites in United States
- Volunteers
- 247 people
- Sponsor
- National Cancer Institute (NCI)
Lymphocytic Leukemia, Chronic
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
This randomized, open-label, parallel group study will assess the effect on response rate and the safety of MabThera added to either bendamustine or chlorambucil in patients with chronic lymphocytic leukemia.
- Trial name
- NCT01056510
- Testing
- bendamustine, chlorambucil, rituximab [MabThera/Rituxan]
- Where
- 85 sites in Finland, France and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Renal Cell Carcinoma
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
- Conditions
- Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced
- Trial name
- NCT04955743
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University